Click here to go to the previous page
Challenges of Precision Medicine: Diagnostics, Reimbursement, Partnership Co-development
Program Code:
560
Date:
Tuesday, June 26, 2012
Time:
12:00 PM to 1:30 PM
EST
CHAIR
:
Dr. Kaitin is Professor and Director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. Dr. Kaitin is an internationally recognized expert on drug development science and policy.
|
PRESENTER
(S):
Ken is the chairman of CISCRP and a Senior Research Fellow, Assistant Professor, at Tufts CSDD. He is a well-known speaker and author, serving on several editorial boards including the Drug Information Journal. Ken holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern U.
|
Felix Frueh, Medco Research Institute, United States
Dr . Romano is Sr VP, Head of Medicines Development Group for Pfizer’s Primary Care Business Unit. He leads a senior team of pharmaceutical executives including heads of statistics & clinical pharmacology, & has the additional responsibility for oversight of Pfizer’s Development Japan organization.
|
Paul Chew, Sanofi US, United States
Prof. Thomas Getzen is Executive Director of the International Health Economics Association, teaches at Temple University, consultant to the Soc. of Actuaries on Forecasting and Macroeconomics of Health, and is author of the leading university textbook HEALTH ECONOMICS & FINANCING.
|
Description
This discussion will help participants leverage real-world evidence generated during product development and throughout the product life cycle to improve the overall quality of patient care. Due to its format, this program offering is not being recorded and will not be available through the post-Annual Meeting Live Learning Center.
Learning Objectives:
Identify the improvements that need to be made to the safety and effectiveness of medical treatments in real-world practice
Evaluate the use of real-world data and comparative effectiveness research to better understand patient needs and improve access to appropriate care
Define the future of therapeutic-diagnostic co-development, its challenges and benefits.